You are here: Industry Insights > NSCLC

News List

Fierce Competition of R&D of KRAS G12C Inhibitors PharmaSources/Yi
January 13, 2022
Recently, the class 1 new drug "ZG19018 Tablets" of Suzhou Zelgen Biopharmaceuticals Co., Ltd. is approved for clinical use in China and the indications are: advanced malignant solid tumors with KRAS G12C mutation.
Closely following Pralsetinib, the second RET inhibitor in China was applied for production PharmaSources/Yi
December 02, 2021
On November 9, according to the CDE official website, the listing application of Eli Lilly's RET inhibitor "Selpercatinib Capsule" was accepted.
US FDA accepts Spectrum Pharmaceuticals’ poziotinib NDA for review pharmaceutical-business-review
February 14, 2022
The US Food and Drug Administration (FDA) has accepted for review Spectrum Pharmaceuticals’ New Drug Application (NDA) for its therapy poziotinib.
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology prnasia
January 17, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
FDA grants Fast Track status to Genprex’s drug for NSCLC treatment Pharmaceutical-Technology
January 05, 2022
In preclinical studies, Reqorsa plus Keytruda were found to be efficient versus Keytruda alone in boosting survival.
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC) prnewswire
November 10, 2021
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces that the U.S. Food...
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung C prnasia
November 02, 2021
Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation...
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC prnasia
October 29, 2021
Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-02) recently completed the first drug administration.
CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC prnasia
September 28, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focus on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines...
WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Sm prnasia
September 13, 2021
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhibitor...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page